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Over the past decades, methicillin-resistant Staphylococcus aureus 
(MRSA) has become a key pathogen in skin and soft-tissue infections 
(SSTIs). The emergence of MRSA in 1961 occurred predominantly 
in patients exposed to health care facilities;1,2 community-acquired 
MRSA (CA-MRSA) isolates were identified in the 1990s.3,4 From 
1993 to 2005, the impact of CA-MRSA nearly tripled emergency 
department SSTI visits in the USA.4 However, there are limited 
data on the incidence and characteristics of SSTIs in sub-Saharan 
Africa, and knowledge of pathogen-specific attributable morbidity 
is lacking.
HIV-infected patients are at markedly increased risk for CA-MRSA 
SSTI. In Chicago the incidence of CA-MRSA SSTIs was 6-fold higher 
among HIV-infected patients than among HIV-negative patients.5 
Given the region’s high HIV seroprevalence rate, the impact of 
MRSA may be particularly pronounced in sub-Saharan Africa.6 A 
multinational surveillance project in eight African hospitals and 
Malta found that 14.8% of clinically significant S. aureus strains 
isolated from patients were resistant to methicillin.7 The prevalence 
of MRSA isolates was even higher in sub-Saharan countries, ranging 
from 16.8% in CÔte d’Ivoire to 29.6% in Nigeria.7 The prevalence 
of HIV in Botswana’s general population is estimated to be 17% 
and reaches nearly 35% among individuals aged 15 - 49 years, the 
highest infection rate after Swaziland.8 An S. aureus colonisation 
rate of 57.5% has been reported among food handlers in Gaborone, 
and 11.2% of bacteraemias in this setting are caused by MRSA, with 
neither study stratifying results by HIV status.9,10 Owing to the high 
prevalence of HIV in Botswana and the emergence of MRSA in blood 
isolates, we hypothesise that MRSA plays a significant role in SSTIs 
in this setting. However, the actual incidence and characteristics of 
SSTIs in this population remain unknown. 
Knowledge of regional antimicrobial susceptibility patterns of 
SSTI pathogens influences treatment decisions and has broad public 
health implications. However, no data describing the antimicrobial 
susceptibility patterns of bacteria causing SSTIs in Botswana are 
available. In 2007 the Botswana Ministry of Health published 
national treatment guidelines for SSTIs, recommending doxycycline 
or penicillin for treatment of skin breaks with clinical signs of 
bacterial infections in adults, and co-trimoxazole, erythromycin or 
penicillin in children.11 These treatment guidelines and the lack of 
epidemiological and antimicrobial susceptibility data on SSTIs set 
the stage for this study. The primary objective was to determine 
the epidemiology of S. aureus SSTIs in hospitalised children and 
adults in Botswana’s capital city of Gaborone over an 8-year period. 
The secondary objective was to describe temporal changes in 
antimicrobial susceptibilities of S. aureus isolates over this period. 
Methods
This retrospective cohort study evaluated SSTI isolates from January 
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Objectives. To study the epidemiology of Staphylococcus aureus 
skin and soft-tissue infections (SSTIs) in hospitalised children 
and adults in Gaborone, Botswana, and to describe the changes in 
antimicrobial susceptibilities of S. aureus isolates over time.
Methods. A retrospective cohort study evaluated SSTI isolates 
from January 2000 to December 2007 at Princess Marina Hospital 
(PMH), a large tertiary referral centre in Gaborone. 
Eligible subjects were those hospitalised at PMH during the 
study period who had a skin or soft-tissue culture yielding a 
bacterial or fungal pathogen. The primary outcome measure was a 
skin or soft-tissue culture yielding S. aureus. Secondary outcomes 
were the organism’s antimicrobial susceptibilities.
Results. S. aureus was detected in 857 (35.8%) of single-organism 
SSTI cultures, and 194 (22.6%) of these isolates were methicillin 
resistant (MRSA). The proportion of MRSA isolates increased over 
time (linear test of trend: p=0.03 from 2000 to 2003), and MRSA 
isolates were more likely than methicillin-susceptible isolates to be 
resistant to commonly used antimicrobials recommended by the 
national SSTI treatment guideline.
Conclusions. We report a high and increasing proportion of 
MRSA SSTIs in Gaborone. This high rate of MRSA resistance to 
currently recommended empiric antibiotics for SSTIs dictates the 
need for revising national guidelines and ongoing prospective 
surveillance of SSTIs in this setting. 
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Gaborone, Botswana. PMH is the largest tertiary care referral centre 
in Botswana, with 530 beds and 20 000 - 30 000 admissions annually. 
PMH provides virtually free health care to citizens of Botswana and 
charges a subsidised fee to non-citizens. Since January 2002, Botswana 
as a whole, and PMH in particular, have provided free highly active 
antiretroviral therapy (HAART) to citizens who are HIV positive and 
who meet specified clinical criteria.8 All patients hospitalised at PMH 
during the study period who had a skin or soft-tissue culture yielding 
a bacterial or fungal pathogen were included. 
SSTI was defined as a culture of non-blood, non-stool or non-
cerebrospinal fluid specimens that yielded a single bacterial or fungal 
pathogen. Most specimens were collected from pus, wound sites, eye, 
ear, throat, vaginal swabs, pleural fluid, pericardial fluid, joint fluid 
or brain abscesses. Polymicrobial skin and soft-tissue cultures were 
considered contaminants and were not included. Multiple cultures 
from an individual patient within 7 days of the original culture were 
considered part of the same episode of SSTI and therefore excluded. 
Clinical wards at PMH were categorised by three parameters: the 
clinical nature of the ward (medical, surgical, intensive care unit, 
accident and emergency, orthopaedic, oncology, ophthalmology, 
radiology); gender (male v. female medical or orthopaedic wards); 
and age of patients (neonatal, paediatric or adult).
Skin and soft-tissue cultures were subjected to microscopy, culture 
and sensitivity testing. Antimicrobial susceptibility patterns of isolates 
were determined by disc-diffusion methods according to Clinical 
Laboratory Standards Institute guidelines.12 Antimicrobial agents 
used were amikacin, ampicillin, amoxicillin-clavulanate, cefotaxime, 
ceftazidime, cephradine, chloramphenicol, ciprofloxacin, clindamycin, 
erythromycin, gentamicin, methicillin, penicillin G, piperacillin, 
tetracycline, trimethoprim, trimethoprim-sulfamethoxazole (TMP-
SMX) and vancomycin. The D test for inducible clindamycin 
resistance was not available. Organisms that were resistant to all of the 
following were classified as multidrug-resistant organisms: ampicillin, 
amoxicillin-clavulanate, cefotaxime, gentamicin, tetracycline, 
trimethoprim and TMP-SMX. The proportion of resistance among 
S. aureus isolates was calculated by dividing the number of resistant 
isolates by the total number of isolates.
Electronic and manual records of the Botswana National Health 
Laboratory were reviewed to identify skin and soft-tissue samples 
that met the study criteria. Demographic data were abstracted 
from the records, including anatomical site of sample, age, gender, 
and the hospital ward at the time of specimen collection. Results 
of antimicrobial susceptibility testing were recorded. Owing to 
laboratory personnel changes, transition from manual to electronic 
medical records and periodic shortages of antibiotics, there were 
missing laboratory records in 39 of the 96 months (41%) of the study 
period – May 2000 - July 2001, December 2002 - June 2003, April 
2004 - February 2005, June 2005 - September 2005, and November 
2005 - December 2005. 
Data were analysed using STATA version 11.0 (Stata Corp., College 
Station, TX). Continuous variables such as age were described using 
mean, median, and range or interquartile range (IQR) values and 
compared using the Wilcoxon rank-sum test. Categorical variables 
were described using counts and percentages and compared using the 
chi-square test. We used univariable logistic regression to determine 
the association of individual covariates with MRSA infection and a 
linear test of trend to identify changes in MRSA prevalence over time. 
Results
During the study period, 2 979 (31.6%) of 9 428 cultures from SSTIs 
were positive. A single organism was isolated from 2 404 (80.7%) of 
the positive cultures. S. aureus was detected in 857 (35.8%) of the 
single-organism cultures.
Table I describes the demographic characteristics of patients with 
S. aureus infections. MRSA accounted for 194 (22.6%) of S. aureus 
isolates. Of patients with an MRSA SSTI, 55.1% were male. Patients 
13 - 49 years of age accounted for almost two-thirds of cases (Table 
I). The most common sites of S. aureus infection or colonisation were 
vaginal swabs (N=53), wounds (N=42) and eyes (N=36). However, 
in the vast majority of S. aureus isolates the anatomical site was 
unspecified ‘pus’ and ‘unspecified fluid’, yielding 2 083 (86.6%) and 
60 (2.5%) of isolates, respectively. 
The male orthopaedic ward had the highest rate of MRSA (42 
cases – 20.6% of MRSA SSTIs). Patients in the male medical ward 
(odds ratio (OR) 4.5, 95% confidence interval (CI) 1.8 - 18.2, p=0.01) 
were at increased odds of having a MRSA SSTI compared with SSTIs 
in the neonatal unit. Fig. 1 displays the annual prevalence of MRSA. 
The lowest proportion of MRSA SSTIs was in 2000 (15.9%) and the 
highest proportion was in 2003 (27%; linear regression p=0.03 from 
2000 to 2003). Although there was an increase in the proportion of 
MRSA from 2000 to 2003, there were no further increases from 2003 
to 2007 (p=0.48). 
S. aureus isolates were routinely tested for susceptibility to 
amoxicillin-clavulanate, cephradine, chloramphenicol, clindamycin, 
erythromycin, gentamicin, methicillin, penicillin, tetracycline and 
vancomycin. Susceptibility to TMP-SMX was not routinely tested; 
results were available for only 18 isolates (Fig. 2). S. aureus was 
most susceptible to vancomycin, clindamycin and chloramphenicol, 
with susceptibility rates of 99.5%, 94.5% and 82.5%, respectively. No 
chloramphenicol susceptibility data were available for 2000.
The antibiotic susceptibilities of MRSA and MSSA are compared in 
Fig. 3. MRSA isolates were more likely to be resistant to clindamycin 
(OR 26.1, 95% CI 15.1 - 46.2, p<0.001), erythromycin (OR 25.5, CI 
15.8 - 41.3, p<0.001) and tetracycline (OR 31.0, 95% CI 17.8 - 55.9, 
p<0.001), compared with MSSA isolates. 
Discussion
The epidemiology and drug susceptibility of S. aureus SSTIs in 
Botswana are described. There is a high proportion of S. aureus 
SSTIs, particularly MRSA, at the tertiary hospital that serves the 
population of southern Botswana. Significant factors that increase the 
odds of MRSA infection among our cohort include age group 13 - 49 
years, and hospitalisation in the intensive care unit, male orthopaedic 
and male medical wards. 
An increasing proportion of MRSA SSTIs in Botswana between 
2000 and 2003 and high levels of MRSA resistance to commonly 
used antibiotics are revealed. There is considerable variation 
in MRSA resistance profiles between regions and countries. In 
Australia, Singapore and Taiwan, MRSA is predominantly resistant 
to ciprofloxacin, clindamycin, erythromycin, gentamicin, TMP/
SMX and tetracycline.13 In KwaZulu-Natal, South Africa, MRSA is 
resistant to clindamycin, erythromycin and TMP/SMX. Similarly, 
MRSA cases in this Botswana study displayed high resistance rates 
to clindamycin, erythromycin and tetracycline. This susceptibility 
pattern is of concern because patients with SSTIs in Botswana are 
routinely treated with one of these medications or penicillin. The 
empiric prescription of penicillin is probably targeting infection by 
Streptococcus group A, but our findings suggest that S. aureus is an 
under-recognised cause of SSTIs in Botswana.  
Despite the Botswana Ministry of Health’s recommendation to 
administer co-trimoxazole as the drug of choice for cutaneous 
bacterial infections, which is supported by current US guidelines 
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advocating TMP-SMX as the first-line therapy against community-
acquired MRSA, S. aureus isolate susceptibilities to TMP-SMX 
were not routinely tested. Additionally, we found that vancomycin, 
the most effective antibiotic against MRSA, is not readily available 
at health centres other than the main hospital. Hence, we propose 
four improvements in managing SSTIs in Botswana: (i) revision 
of Botswana’s national SSTI guidelines, including discontinuing 
advocating penicillin as empiric treatment for SSTIs in a setting where 
S. aureus accounts for more than a third of culture-positive SSTIs and 
virtually all of these S. aureus isolates are resistant to this class of 
antibiotics (this has been achieved, as Botswana’s national antibiotic 
guidelines, informed by information from this study, were revised 
in July 2010); (ii) TMP-SMX susceptibility testing of all S. aureus 
SSTI isolates; (iii) improved hospital infection control guidelines and 
practices to prevent MRSA transmission in the hospital setting; and 
(iv) vancomycin availability in district hospitals with strict guidelines 
governing its use.
Limitations of this study include: (i) missing laboratory data from 
our study period may have contributed to an underestimate of SSTI 
Fig. 1. Annual proportion of MRSA, 2000 - 2007. Linear regression for 2000 - 
2003 shows p=0.03; regression for 2000 - 2007, p=0.48.
Fig. 1. Annual proportion of MRSA, 2000 
p=0.03; regression for 2000 - 2007, 
 
 
 
- 2007. Linear regression for 2000 - 2003 shows 
p=0.48. 
 
Table I. Demographic characteristics of patients with Staphylococcus aureus SSTI (N=857)
Patient characteristic No. (%) with MSSA No. (%) with MRSA Unadjusted OR (95% CI) p
Age group (N=818)
<1 mo. 26 (4.1) 8 (4.4) Reference -
1 - 11.9 mo. 12 (1.9) 2 (1.1) 0.5 (0.05 - 3.4) 0.5
1 - 4.9 yrs 31 (4.9) 9 (4.9) 0.9 (0.3 - 3.3) 0.9
5 - 12.9 yrs 99 (15.7) 17 (9.3) 0.6 (0.2 - 1.7) 0.2
13 - 49 yrs 327 (51.8) 114 (62.3) 1.1 (0.5 - 3) 0.8
>50 yrs 136 (21.6) 33 (18) 0.8 (0.3 - 2.2) 0.6
Gender (N=706)
Female 253 (42.2) 93 (44.9) 1.1 (0.8 - 1.6) 0.5
Ward type (N=780)
Neonatal nursery unit 26 (4.5) 9 (4.4) Reference -
Paediatric medical ward 23 (4) 2 (1) 0.3 (0.02 - 1.4) 0.08
Paediatric surgical ward 103 (17.9) 25 (12.3) 0.7 (0.3 - 1.9) 0.4
Male medical ward 7 (1.2) 11 (5.4) 4.5 (1.2 - 18.2) 0.01
Male surgical ward 60 (10.4) 32 (15.7) 1.5 (0.6 - 4.2) 0.3
Female medical ward 17 (3) 9 (4.4) 1.5 (0.4 - 5.3) 0.5
Female surgical ward 48 (8.3) 21 (10.3) 1.3 (0.5 - 3.6) 0.6
ICU 8 (1.4) 8 (3.9) 2.9 (0.7 - 11.8) 0.09
A&E 62 (10.8) 2 (1) 0.09 (0.009 - 0.5) 0.001
Male orthopaedic 132 (22.9) 42 (20.6) 0.9 (0.4 - 2.4) 0.8
Female orthopaedic 68 (11.8) 30 (14.7) 1.3 (0.5 - 3.5) 0.6
Private 9 (1.6) 6 (2.9) 1.9 (0.4 - 8.2) 0.3
Gynaecology 13 (2.3) 7 (3.4) 1.6 (0.4 - 6) 0.5
MSSA = methicillin-susceptible S. aureus; MRSA = methicillin-resistant S. aureus; OR = odds ratio; CI = confidence interval; ICU = intensive care unit; A&E = accident and emergency unit.
Fig. 2. Antibiotic susceptibility profiles for S. aureus, 2000 - 2007. Antimi-
crobial susceptibility data were not available at all times. This is why no row 
reaches 100%. 
Fig. 2. Antibiotic susceptibility profiles for S. aureus, 2000 - 2007. Antimicrobial susceptibility 
data were not available at all times. This is why no row reaches 100%.  
 
 
 
Tetracycline (n=771)
Erythromycin (n=757)
Cephadrine (n=736)
Methicillin (n=663)
Gentamicin (n=784)
TMP-SMX (n=18)
Augmentin (n=588)
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prevalence; (ii) the anatomical site was not known for most S. aureus 
isolates, making it impossible to define the exact nature of each SSTI; 
(iii) owing to the retrospective study design, standard laboratory 
techniques may have shifted over the 8-year study period; and (iv) 
our retrospective design makes our results susceptible to potential 
biases of studies of similar design. 
In summary, we found a high and increasing proportion of MRSA 
SSTIs in Gaborone. Additionally, the high rate of MRSA resistance 
to currently recommended empiric antibiotics for SSTIs dictates 
the need for revising national guidelines and ongoing prospective 
surveillance of SSTIs in this setting. 
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I love to watch the busy EGRET
(both the she-gret and the he-gret)
But what a way to earn your keep. . . 
Picking ticks off cows and sheep!
 
The egret has a graceful torso
And the HERON even more so.
See him, stone-still, in the creek,
S-shaped neck and dagger beak;
All-of-a-sudden with a swish!
Look – the heron has a fish!
 
Wheeling high up in the sky
The SEAGULL flies with raucous cry.
When underneath, you should be careful,
Or you’ll land up with a hairful.
I wish the awkward HA-DI-DAH
Would learn to whistle, tweet or baa
A brownish bird, with fearsome beak
She calls her mate with rasping shriek
But someone loves the ha-di-dah
It is of course the ha-di-ma.
 
I’ve the greatest respect for the PLOVER
He is always so true to his lover
Her eggs he will shield
So exposed in the field
And he’ll never run off with anover.
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